Funded Pharmaceutical Manufacturing Startups
Six pharmaceutical manufacturing financings are shown, spanning 2022-11-22 (Lenz Therapeutics, Del Mar, CA) through 2025-04-08 (Solvet, Calgary, Alberta).
Six pharmaceutical manufacturing financings are shown, spanning 2022-11-22 (Lenz Therapeutics, Del Mar, CA) through 2025-04-08 (Solvet, Calgary, Alberta). Among disclosed rounds, the largest is Lenz Therapeutics at $49M on 2022-11-22, which sits well above the rest of the disclosed amounts (Corsair Pharma $23M on 2023-09-20, Egetis Therapeutics AB $27M on 2023-10-10, and India Globalization Capital $3M on 2024-03-26).
A cluster appears around mid-to-late 2023: three of the disclosed entries (Egetis Therapeutics AB $27M on 2023-10-10, Corsair Pharma $23M on 2023-09-20, and PannTheraPi with undisclosed amount on 2023-06-23) fall within roughly four months. Geography is split across North America and Europe, with two entries in the United States (India Globalization Capital in Bethesda, MD; Corsair Pharma and Lenz Therapeutics in California) and two in Europe (Egetis Therapeutics AB in Stockholm; PannTheraPi in Nîmes), plus Solvet in Canada. Stage/amount reporting is mixed: 2 of 6 rows list undisclosed amounts (Solvet 2025-04-08; PannTheraPi 2023-06-23).
Most recent rounds
6 shownRelated listings
Frequently asked
What is the largest disclosed round here, and does it dwarf the next-largest?
The largest disclosed amount is Lenz Therapeutics’ $49M on 2022-11-22, and it is significantly larger than the next-largest disclosed rounds in this slice: Egetis Therapeutics AB’s $27M (2023-10-10) and Corsair Pharma’s $23M (2023-09-20).
Are there any time clusters in these pharmaceutical manufacturing rounds?
Yes. In mid-to-late 2023, three entries cluster between 2023-06-23 and 2023-10-10 (PannTheraPi on 2023-06-23 with undisclosed amount, Corsair Pharma $23M on 2023-09-20, and Egetis Therapeutics AB $27M on 2023-10-10).
Which cities or geographies are over-represented among the companies shown?
California appears twice among the US-based rows: Corsair Pharma (Sunnyvale, CA) on 2023-09-20 and Lenz Therapeutics (Del Mar, CA) on 2022-11-22. Otherwise, the list is geographically distributed across Canada (Solvet, Calgary), the US East Coast (India Globalization Capital, Bethesda), and two European cities (Stockholm and Nîmes).
How many rounds are ‘Series Unknown’ or undisclosed on amount, and what does that imply for comparisons?
Across 6 rows, 3 list ‘Series Unknown’ (Solvet, Egetis Therapeutics AB, and PannTheraPi) and 2 list undisclosed amounts (Solvet 2025-04-08; PannTheraPi 2023-06-23). That means only 4 disclosed amounts can be compared directly ($3M, $23M, $27M, $49M).
Is there an outlier beyond size, based on stage or reporting?
India Globalization Capital is a size outlier on disclosed amounts at $3M on 2024-03-26, far below the other disclosed rounds. In terms of reporting, Solvet (2025-04-08) and PannTheraPi (2023-06-23) are amount-undisclosed, limiting any size-based pattern for those two entries.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.